Englander Institute for Precision Medicine

Publications

Found 583 results
Author Title Type [ Year(Asc)]
2023
Weinstock JS, Gopakumar J, Burugula BBharathi, Uddin MMesbah, Jahn N, Belk JA, Bouzid H, Daniel B, Miao Z, Ly N et al..  2023.  Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis.. Nature. 616(7958):755-763.
Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, Agostini M, Agostinis P, Alnemri ES, Altucci L et al..  2023.  Apoptotic cell death in disease-Current understanding of the NCCD 2023.. Cell Death Differ. 30(5):1097-1154.
Johnson JL, Yaron TM, Huntsman EM, Kerelsky A, Song J, Regev A, Lin T-Y, Liberatore K, Cizin DM, Cohen BM et al..  2023.  An atlas of substrate specificities for the human serine/threonine kinome.. Nature. 613(7945):759-766.
Santambrogio L.  2023.  Autoimmunity to the modified self.. Science. 379(6637):1092-1093.
Powles T, Park SHoon, Caserta C, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Sternberg CN, Bellmunt J et al..  2023.  Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.. J Clin Oncol. 41(19):3486-3492.
Grivas P, Park SHoon, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar SS et al..  2023.  Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.. Eur Urol. 84(1):95-108.
Hajirasouliha I, Semrau S.  2023.  Back in 3D-a report on Genome Informatics 2022.. Genome Biol. 24(1):57.
Minoli M, Cantore T, Hanhart D, Kiener M, Fedrizzi T, La Manna F, Karkampouna S, Chouvardas P, Genitsch V, Rodriguez-Calero A et al..  2023.  Bladder cancer organoids as a functional system to model different disease stages and therapy response.. Nat Commun. 14(1):2214.
Santambrogio L, Marrack P.  2023.  The broad spectrum of pathogenic autoreactivity.. Nat Rev Immunol. 23(2):69-70.
Dhaouadi N, Vitto VAngela Mar, Pinton P, Galluzzi L, Marchi S.  2023.  Ca signaling and cell death.. Cell Calcium. 113:102759.
Guilbaud E, Kroemer G, Galluzzi L.  2023.  Calreticulin exposure orchestrates innate immunosurveillance.. Cancer Cell. 41(6):1014-1016.
Weiss TJ, Crawford ER, Posada V, Rahman H, Liu T, Murphy BM, Arnold TE, Gray S, Hu Z, Hennessey RC et al..  2023.  Cell-intrinsic melanin fails to protect melanocytes from ultraviolet-mutagenesis in the absence of epidermal melanin.. Pigment Cell Melanoma Res. 36(1):6-18.
Klapp V, Buqué A, Bloy N, Sato A, Yamazaki T, Zhou XKathy, Formenti SC, Galluzzi L, Petroni G.  2023.  Cellular senescence in the response of HR breast cancer to radiotherapy and CDK4/6 inhibitors.. J Transl Med. 21(1):110.
Higano CS, George DJ, Shore ND, Sartor O, Miller K, Conti PS, Sternberg CN, Saad F, Sade JPablo, Bellmunt J et al..  2023.  Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer.. EClinicalMedicine. 60:101993.
Shah SB, Carlson CR, Lai K, Zhong Z, Marsico G, Lee KM, Vélez NEFélix, Abeles EB, Allam M, Hu T et al..  2023.  Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas.. Nat Mater. 22(4):511-523.
Popic V, Rohlicek C, Cunial F, Hajirasouliha I, Meleshko D, Garimella K, Maheshwari A.  2023.  Cue: a deep-learning framework for structural variant discovery and genotyping.. Nat Methods. 20(4):559-568.
Liu W, Newhall KP, Khani F, Barlow LM, Nguyen D, Gu L, Eng K, Bhinder B, Uppal M, Récapet C et al..  2023.  The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.. Cancer Res. 83(4):506-520.
Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, E Crawford D, Shore N, Kopyltsov E, Kalebasty ARezazadeh, Bögemann M et al..  2023.  Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.. J Clin Oncol. 41(20):3595-3607.
Darabedian N, Ji W, Fan M, Lin S, Seo H-S, Vinogradova EV, Yaron TM, Mills EL, Xiao H, Senkane K et al..  2023.  Depletion of creatine phosphagen energetics with a covalent creatine kinase inhibitor.. Nat Chem Biol. 19(7):815-824.
Yusupova M, Zhou D, You J, Gonzalez-Guzman J, Ghanta MB, Pu H, Abdel-Malek Z, Chen Q, Gross SS, D'Orazio J et al..  2023.  Distinct cAMP signaling microdomains differentially regulate melanosomal pH and pigmentation.. J Invest Dermatol.
Klapp V, Álvarez-Abril B, Leuzzi G, Kroemer G, Ciccia A, Galluzzi L.  2023.  The DNA Damage Response and Inflammation in Cancer.. Cancer Discov. 13(7):1521-1545.
Galluzzi L, Aryankalayil MJ, C Coleman N, Formenti SC.  2023.  Emerging evidence for adapting radiotherapy to immunotherapy.. Nat Rev Clin Oncol.
Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..  2023.  Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.
Galassi C, Galluzzi L.  2023.  Epigenetic escape of immunosurveillance by malignant cell precursors.. EMBO J. 42(10):e114050.
Li D, Zhan Y, Wang N, Tang F, Lee CJ, Bayshtok G, Moore AR, Wong EWP, Pachai MR, Xie Y et al..  2023.  ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer.. Sci Adv. 9(14):eadc9446.